NEW YORK, June 20 - Oxford Glycosciences and NeoGenesis have agreed to partner in an effort to identify small molecule drugs for OGS' protein targets, the companies said Wednesday. 

OGS, of Oxford, UK, will provide an undisclosed number of protein targets to NeoGenesis, and pay NeoGenesis research fees, milestone payments, and royalties for lead compounds that the company identifies. OGS will commercialize any lead compounds, and is also making an undisclosed equity investment in NeoGenesis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.